Toll-Like Receptor (TLR)-1/2 Triggering of Multiple Myeloma Cells Modulates Their Adhesion to Bone Marrow Stromal Cells and Enhances Bortezomib-Induced Apoptosis

Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP

(2014) L. E. Perez et al.   JOURNAL OF IMMUNOLOGY

Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

(2013) Jahangir Abdi et al.   PLoS One

Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells

(2013) J Abdi et al.   Blood Cancer Journal

Pathogenesis of Myeloma

(2011) Kenneth C. Anderson et al.   Annual Review of Pathology-Mechanisms of Disease

Integrin  7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

(2011) P. Neri et al.   BLOOD

The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma

(2011) Jahangir Abdi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Expression of integrins and Toll-like receptors in cervical cancer: Effect of infectious agents

(2011) Jeff Werner et al.   Innate Immunity

Toll-like Receptor-4 (TLR4) Down-regulates MicroRNA-107, Increasing Macrophage Adhesion via Cyclin-dependent Kinase 6

(2011) Elizabeth J. Hennessy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation

(2011) Xudong Wang et al.   LEUKEMIA & LYMPHOMA

Positioning NK- B in multiple myeloma

(2010) B. Klein   BLOOD

Classical and/or alternative NF- B pathway activation in multiple myeloma

(2010) Y. N. Demchenko et al.   BLOOD

Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-κB

(2010) Yang Xu et al.   BRITISH JOURNAL OF HAEMATOLOGY

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

(2010) M. S. van der Veer et al.   HAEMATOLOGICA

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

Poly I:C-induced expression of intercellular adhesion molecule-1 in intestinal epithelial cells

(2009) D. Omagari et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

TLR3 Ligand Induces NF- B Activation and Various Fates of Multiple Myeloma Cells Depending on IFN-  Production

(2009) D. Chiron et al.   JOURNAL OF IMMUNOLOGY

Toll-like receptors: lessons to learn from normal and malignant human B cells

(2008) D. Chiron et al.   BLOOD

Inflammation and cancer: Role of nuclear factor-kappaB activation

(2008) Shin Maeda et al.   CANCER SCIENCE

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

(2008) H. Gu et al.   MOLECULAR CANCER THERAPEUTICS

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE

Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells

(2008) R Chen et al.   ONCOGENE